guest ::
| Home > Publications database > Does Estimated Pulse Wave Velocity Add Prognostic Information?: MORGAM Prospective Cohort Project. > print |
| Home > Publications database > Does Estimated Pulse Wave Velocity Add Prognostic Information?: MORGAM Prospective Cohort Project. > print |
| 001 | 154464 | ||
| 005 | 20240229123102.0 | ||
| 024 | 7 | _ | |a 10.1161/HYPERTENSIONAHA.119.14088 |2 doi |
| 024 | 7 | _ | |a pmid:32275189 |2 pmid |
| 024 | 7 | _ | |a 0194-911X |2 ISSN |
| 024 | 7 | _ | |a 0194-911x |2 ISSN |
| 024 | 7 | _ | |a 0362-4323 |2 ISSN |
| 024 | 7 | _ | |a 1524-4563 |2 ISSN |
| 024 | 7 | _ | |a altmetric:79910154 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2020-00786 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Vishram-Nielsen, Julie K K |b 0 |
| 245 | _ | _ | |a Does Estimated Pulse Wave Velocity Add Prognostic Information?: MORGAM Prospective Cohort Project. |
| 260 | _ | _ | |a Baltimore, Md. |c 2020 |b Williams & Wilkins |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1608045479_16491 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2020 Jun;75(6):1420-1428 |
| 520 | _ | _ | |a The Reference Values for Arterial Stiffness Collaboration has derived an equation using age and mean blood pressure to estimated pulse wave velocity (ePWV), which predicted cardiovascular events independently of Systematic COoronary Risk Evaluation (SCORE) and Framingham Risk Score. The study aim was to investigate the independent association between ePWV and clinical outcomes in 107 599 apparently healthy subjects (53% men) aged 19 to 97 years from the MORGAM Project who were included between 1982 and 2002 in 38 cohorts from 11 countries. Using multiple Cox-regression analyses, the predictive value of ePWV was calculated adjusting for country of inclusion and either SCORE, Framingham Risk Score, or traditional cardiovascular risk factors (age, sex, smoking, systolic blood pressure, body mass index [BMI], total and high-density lipoprotein cholesterol). Cardiovascular mortality consisted of fatal stroke, fatal myocardial infarction, or coronary death, and the composite cardiovascular end point consisted of stroke, myocardial infarction, or coronary death. Model discrimination was assessed using Harrell's C-statistic. Adjusting for country and logSCORE or Framingham Risk Score, ePWV was associated with all-cause mortality (hazard ratio, 1.23 [95% CI 1.20-1.25] per m/s or 1.32 [1.29-1.34]), cardiovascular mortality (1.26 [1.21-1.32] or 1.35 [1.31-1.40]), and composite cardiovascular end point (1.19 [1.16-1.22] or 1.23 [1.20-1.25]; all P<0.001). However, after adjusting for traditional cardiovascular risk factors, ePWV was only associated with all-cause mortality (1.15 [1.08-1.22], P<0.001) and not with cardiovascular mortality (0.97 [0.91-1.03]) nor composite cardiovascular end point (1.10 [0.97-1.26]). The areas under the last 3 receiver operator characteristic curves remained unchanged when adding ePWV. Elevated ePWV was associated with subsequent mortality and cardiovascular morbidity independently of systematic coronary risk evaluation and Framingham Risk Score but not independently of traditional cardiovascular risk factors. |
| 536 | _ | _ | |a 313 - Cancer risk factors and prevention (POF3-313) |0 G:(DE-HGF)POF3-313 |c POF3-313 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Laurent, Stephane |b 1 |
| 700 | 1 | _ | |a Nilsson, Peter M |b 2 |
| 700 | 1 | _ | |a Linneberg, Allan |b 3 |
| 700 | 1 | _ | |a Sehested, Thomas S G |b 4 |
| 700 | 1 | _ | |a Greve, Sara V |b 5 |
| 700 | 1 | _ | |a Pareek, Manan |b 6 |
| 700 | 1 | _ | |a Palmieri, Luigi |b 7 |
| 700 | 1 | _ | |a Giampaoli, Simona |b 8 |
| 700 | 1 | _ | |a Donfrancesco, Chiara |b 9 |
| 700 | 1 | _ | |a Kee, Frank |b 10 |
| 700 | 1 | _ | |a Mancia, Giuseppe |b 11 |
| 700 | 1 | _ | |a Cesana, Giancarlo |b 12 |
| 700 | 1 | _ | |a Veronesi, Giovanni |b 13 |
| 700 | 1 | _ | |a Kuulasmaa, Kari |b 14 |
| 700 | 1 | _ | |a Salomaa, Veikko |b 15 |
| 700 | 1 | _ | |a Kontto, Jukka |b 16 |
| 700 | 1 | _ | |a Palosaari, Tarja |b 17 |
| 700 | 1 | _ | |a Sans, Susana |b 18 |
| 700 | 1 | _ | |a Ferrieres, Jean |b 19 |
| 700 | 1 | _ | |a Dallongeville, Jean |b 20 |
| 700 | 1 | _ | |a Söderberg, Stefan |b 21 |
| 700 | 1 | _ | |a Moitry, Marie |b 22 |
| 700 | 1 | _ | |a Drygas, Wojciech |b 23 |
| 700 | 1 | _ | |a Tamosiunas, Abdonas |0 P:(DE-HGF)0 |b 24 |
| 700 | 1 | _ | |a Peters, Annette |0 P:(DE-HGF)0 |b 25 |
| 700 | 1 | _ | |a Brenner, Hermann |0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2 |b 26 |u dkfz |
| 700 | 1 | _ | |a Njolstad, Inger |b 27 |
| 700 | 1 | _ | |a Olsen, Michael H |b 28 |
| 700 | 1 | _ | |a Project, MORGAM |b 29 |e Collaboration Author |
| 773 | _ | _ | |a 10.1161/HYPERTENSIONAHA.119.14088 |0 PERI:(DE-600)2094210-2 |n 6 |p 1420-1428 |t Hypertension |v 75 |y 2020 |x 1524-4563 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:154464 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 24 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 25 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 26 |6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-313 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Cancer risk factors and prevention |x 0 |
| 914 | 1 | _ | |y 2020 |
| 915 | _ | _ | |a Allianz-Lizenz |0 StatID:(DE-HGF)0410 |2 StatID |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b HYPERTENSION : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b HYPERTENSION : 2017 |
| 920 | 1 | _ | |0 I:(DE-He78)C070-20160331 |k C070 |l C070 Klinische Epidemiologie und Alternf. |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)C120-20160331 |k C120 |l Präventive Onkologie |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C070-20160331 |
| 980 | _ | _ | |a I:(DE-He78)C120-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|